Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
28.41
+0.24 (0.85%)
At close: Jun 17, 2026, 4:00 PM EDT
28.34
-0.07 (-0.25%)
After-hours: Jun 17, 2026, 5:25 PM EDT
Sutro Biopharma Revenue
Sutro Biopharma had revenue of $14.52M in the quarter ending March 31, 2026, a decrease of -16.53%. This brings the company's revenue in the last twelve months to $99.61M, up 49.94% year-over-year. In the year 2025, Sutro Biopharma had annual revenue of $102.48M with 65.18% growth.
Revenue (ttm)
$99.61M
Revenue Growth
+49.94%
P/S Ratio
4.73
Revenue / Employee
$748,932
Employees
133
Market Cap
470.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 102.48M | 40.44M | 65.18% |
| Dec 31, 2024 | 62.04M | -91.69M | -59.64% |
| Dec 31, 2023 | 153.73M | 85.96M | 126.84% |
| Dec 31, 2022 | 67.77M | 5.89M | 9.52% |
| Dec 31, 2021 | 61.88M | 19.16M | 44.84% |
| Dec 31, 2020 | 42.72M | -14.00K | -0.03% |
| Dec 31, 2019 | 42.74M | 4.32M | 11.24% |
| Dec 31, 2018 | 38.42M | -13.32M | -25.75% |
| Dec 31, 2017 | 51.74M | -7.99M | -13.38% |
| Dec 31, 2016 | 59.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 180.25M |
| Arvinas | 89.40M |
| 4D Molecular Therapeutics | 88.24M |
| XOMA Royalty | 48.56M |
| Prime Medicine | 4.03M |
| ProKidney | 889.00K |
| Altimmune | 36.00K |
STRO News
- 6 days ago - Sutro Biopharma assumed with a Buy at Truist - TheFly
- 12 days ago - Sutro Biopharma Transcript: AGM 2026 - Transcripts
- 13 days ago - Sutro Biopharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 20 days ago - Sutro Biopharma initiated with an Overweight at Barclays - TheFly
- 21 days ago - Sutro Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 26 days ago - Sutro Biopharma price target raised to $10 from $9 at BofA - TheFly
- 4 weeks ago - Wedbush upgrades Sutro Biopharma to Outperform, raises price target to $60 - TheFly
- 4 weeks ago - Sutro Biopharma upgraded to Outperform from Neutral at Wedbush - TheFly